All In Biotech

Drug Trial Radar · NCT00337727

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC)

Last checked: Nov 19, 2026Latest source record: Jun 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 848 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

848

Actual

Start

Jan 1, 2007

Primary completion

Oct 28, 2008

Study completion Nov 19, 2008

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of chemotherapy may opt to participate in an optional second cycle during which the patient will receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant will be given in place of the oral formulation on study day one. Study drug administration on subsequent days will be given orally as in cycle 1.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

  • aprepitantDrug

    aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.

  • Comparator: ondansetronDrug

    Ondansetron 8 mg capsule Three day treatment period.

  • Comparator: dexamethasoneDrug

    dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.

  • Comparator: fosaprepitant dimeglumineDrug

    fosaprepitant dimeglumine 115 mg

  • Comparator; Placebo (unspecified)Drug

    dexamethasone 12mg Pbo tablets.

  • Comparator; Placebo (unspecified)Drug

    Aprepitant 80 mg \& 125 mg Pbo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Who Reported No VomitingTime frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.